Literature DB >> 16447002

Pain and return to daily activities after uterine artery embolization and hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial.

Wouter J K Hehenkamp1, Nicole A Volkers, Erwin Birnie, Jim A Reekers, Willem M Ankum.   

Abstract

PURPOSE: To evaluate the safety and efficacy of uterine artery embolization (UAE) and hysterectomy for symptomatic uterine fibroids by means of a randomized controlled trial. The present paper analyses short-term outcomes, i.e., pain and return to daily activities.
METHODS: Patients were randomized (1:1) to UAE or hysterectomy. Pain was assessed during admission and after discharge, both quantitatively and qualitatively, using a numerical rating scale and questionnaires. Time to return to daily activities was assessed by questionnaire.
RESULTS: Seventy-five patients underwent hysterectomy and 81 patients underwent UAE. UAE patients experienced significantly less pain during the first 24 hr after treatment (p = 0.012). Non-white patients had significantly higher pain scores. UAE patients returned significantly sooner to daily activities than hysterectomy patients (for paid work: 28.1 versus 63.4 days; p < 0.001). In conclusion, pain appears to be less after UAE during hospital stay. Return to several daily activities was in favor of UAE in comparison with hysterectomy.

Entities:  

Mesh:

Year:  2006        PMID: 16447002     DOI: 10.1007/s00270-005-0195-9

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  17 in total

1.  Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial.

Authors:  Anu Ruuskanen; Maritta Hippeläinen; Petri Sipola; Hannu Manninen
Journal:  Eur Radiol       Date:  2010-06-06       Impact factor: 5.315

Review 2.  Fibroids (uterine myomatosis, leiomyomas).

Authors:  Anne Lethaby; Beverley Vollenhoven
Journal:  BMJ Clin Evid       Date:  2015-06-02

3.  Clinical care of patients undergoing uterine artery embolization.

Authors:  Thuong G Van Ha; Natasha Li
Journal:  Semin Intervent Radiol       Date:  2006-12       Impact factor: 1.513

Review 4.  Fibroids (uterine myomatosis, leiomyomas).

Authors:  Anne Lethaby; Beverley Vollenhoven
Journal:  BMJ Clin Evid       Date:  2011-01-11

5.  Uterine artery embolization, surgery and high intensity focused ultrasound in the treatment of uterine fibroids: a network meta-analysis.

Authors:  Haijun Gao; Tianping Li; Dianxun Fu; Jun Wei
Journal:  Quant Imaging Med Surg       Date:  2021-09

6.  Pain after uterine fibroid embolisation is associated with the severity of myometrial ischaemia on magnetic resonance imaging.

Authors:  Anu Ruuskanen; Petri Sipola; Maritta Hippeläinen; Marion Wüstefeld; Hannu Manninen
Journal:  Eur Radiol       Date:  2009-12       Impact factor: 5.315

7.  Characteristics of vascular supply to uterine leiomyoma: an analysis of digital subtraction angiography imaging in 518 cases.

Authors:  Chun-Lin Chen; Yu-Jing Xu; Ping Liu; Jiang-Hong Zhu; Ben Ma; Bei-Lan Zeng; Yan Zhou; Li Wang; Yi-Xin Tang; Chuan-Jia Guo
Journal:  Eur Radiol       Date:  2012-09-22       Impact factor: 5.315

Review 8.  [Follow-up in uterine fibroid embolization].

Authors:  D Vorwerk
Journal:  Radiologe       Date:  2008-07       Impact factor: 0.635

9.  Sexuality and body image after uterine artery embolization and hysterectomy in the treatment of uterine fibroids: a randomized comparison.

Authors:  Wouter J K Hehenkamp; Nicole A Volkers; Wouter Bartholomeus; Sjoerd de Blok; Erwin Birnie; Jim A Reekers; Willem M Ankum
Journal:  Cardiovasc Intervent Radiol       Date:  2007 Sep-Oct       Impact factor: 2.740

10.  Pain management during uterine artery embolization for symptomatic uterine fibroids.

Authors:  L E Lampmann; P N Lohle; A Smeets; P F Boekkooi; H Vervest; C M van Oirschot; R C Bremer
Journal:  Cardiovasc Intervent Radiol       Date:  2007-05-29       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.